Related Experiment Video
Updated: May 20, 2025
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.6K
Innovative therapeutics for renoprotection: Where we are
Monica Cortinovis1, Norberto Perico1, Giuseppe Remuzzi1
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Pharmacological Reviews
|May 18, 2025
Summary
Novel therapeutics like SGLT2 inhibitors and finerenone significantly improve outcomes for chronic kidney disease (CKD) patients. Personalized, multidrug approaches offer powerful new tools to slow or prevent proteinuric CKD progression.
Area of Science:
- Nephrology
- Pharmacology
- Public Health
Background:
- Chronic kidney disease (CKD) is a global health concern, increasing risks of kidney failure, cardiovascular events, and mortality.
- Historically, renin-angiotensin system inhibitors were the primary treatment to slow CKD progression and reduce cardiovascular risks.
Purpose of the Study:
- To review the evolving landscape of CKD treatment, focusing on proteinuric CKD.
- To present established and novel kidney protective drugs and discuss emerging therapeutic interventions.
Main Methods:
- Review of landmark clinical trials and recent evidence for CKD therapeutics.
- Focus on pharmacological interventions, including sodium-glucose cotransporter-2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists.
- Discussion of ongoing clinical investigations for CKD progression.
Main Results:
- Sodium-glucose cotransporter-2 inhibitors benefit both diabetic and nondiabetic kidney disease.
- Finerenone and semaglutide show efficacy in diabetic kidney disease.
- Novel agents significantly improve kidney and cardiovascular outcomes when added to existing therapies.
Conclusions:
- Personalized and multidrug interventions are becoming increasingly feasible and effective.
- These advanced strategies hold promise for slowing or preventing the progression of proteinuric CKD.
- The availability of new kidney protective agents offers hope for improved patient outcomes in the coming decades.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
347
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
347
01:25Antihypertensive Drugs: Direct Renin Inhibitors
464
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
464
01:28Renal Drug Excretion: Tubular Secretion
100
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
100
01:22Heart Failure Drugs: Diuretics
306
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
306
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
422
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
422
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K